What happened
Shares of the clinical-stage biotech Novavax (NASDAQ: NVAX) fell by as much as 18.2% in pre-marketing trading this morning. What's going on? Investors -- or more likely day traders -- appear to be disappointed in the company's updates for both its experimental NanoFlu, and respiratory syncytial virus (RSV), vaccine candidates yesterday.
Image source: Getty Images.
So what
Instead of the major clinical update some investors were expecting, Novavax simply noted, per its press release, that the ongoing late-stage RSV study in pregnant women remains on track for a mid-2018 interim analysis, and the company is accelerating enrollment to meet this target.
The company's progress on its NanoFlu vaccine candidate was even less noteworthy from an investing standpoint. On this front, Novavax basically provided a summary of the current state of the flu market, and noted that a new, more effective vaccine is needed. Hence, the company plans on preparing a Phase 1/2 data package to be released next February.
Now what
In short, Novavax released a nothing burger yesterday -- drawing the ire of investors that bought this stock in anticipation of a more robust news event. Unfortunately, it's commonplace for companies like Novavax, that are struggling to meet the minimum bid requirements for the Nasdaq Stock Exchange, to release fairly minor business or clinical updates on a regular basis. On the bright side, we now know that Novavax doesn't have anything truly meaningful on the docket until next February when the NanoFlu data package should be ready. So until then, it might be best to simply watch this developmental-stage biotech from the safety of the sidelines.
10 stocks we like better than Novavax
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Novavax wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of December 4, 2017
George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
